Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma Abstract #2249

Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.
Aim(s): We present the case of a patient with refractory hypoglycemic syndrome from metastatic pancreatic NET treated with Pasireotide i.m. after the failure of different lines of treatment
Materials and methods: In 2013 a 60-yr old woman was diagnosed with a 15 mm non-functioning pancreatic NET with multiple liver metastases. (Ki67 10%). From 2013 to 2016 she underwent chemotherapy (STZ/5-FLU), 2 TACE of liver lesions, treatment with Everolimus 10 mg/day with Octreotide LAR 30 mg, and finally PRRT with 177Lu-octreotate. She developed a myelodyslpastic syndrome as a consequence of the treatments. In January 2017 she showed frequent hyperinsulinemic hypoglycemic episodes and was treated with diazoxide, which was stopped due to nausea and anorexia, octreotide LAR 30 mg, im glucagon and iv cortisone. Due to the persistence of severe hypoglycemic events she needed continuous iv 10% dextrose infusion. Given the pancytopenia, Everolimus could not be used again.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Maria Vittoria Davì

To read results and conclusion, please login ...

Further abstracts you may be interested in

#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma
Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels<30 mg/dl, insulin 150 microUI/ml, and C-peptide at upper normal limits. Endocrinologist prescribed prednisone, diazoxide and recombinant glucagon for hypoglicemic crisis, with little benefit. In March 2010, the patient was given radio-labelled Lu-177-OCTREOTATE treatment. After three cycles, hypoglicemic symptoms were still uncontrolled. CT scan showed stable disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Anna Ferrero
Authors: Ferrero A, Bellini E, Brizzi M P, Pia A, ...
#1257 A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series
Introduction: Malignant insulinoma is traditionally considered extremely rare and its natural history variable.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. Run Yu
Authors: Yu R, Nissen N N, Hendifar A, Fan X, ...
#1390 Ectopic Malignant Insulinoma with Multiple Liver Metastases: A Case Report
Introduction: Malignant insulinoma arising from ectopic pancreas is very rare.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Liu Q, Luo J, Li C, Zhu Z H, ...
#2124 A Case Report of a Malignant Insulinoma
Introduction: Despite rare (1-2% of pancreatic tumors/PT), insulinomas are the most common functional pNET. The diagnosis is established by demonstrating inappropriately high serum insulin levels during a spontaneous or induced episode of hypoglycemia.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Theodoros Tegos
Keywords: malignant, insulinoma
#270 Insulinoma: A Rare Tumor?
Introduction: Insulinoma, a pancreatic ß-cell tumor, comprises 55% of neuroendocrine tumors with an annual incidence of 3-10/million. 10% are malignant, 10% are multiple and half of them present in MEN-1.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Vasiliki Daraki